Trial Profile
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention (Augustus)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Vitamin K antagonists; Warfarin
- Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke; Thrombosis
- Focus Adverse reactions
- Acronyms AUGUSTUS
- Sponsors Bristol-Myers Squibb
- 07 Nov 2022 Results(n=2290) assessing Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention presented at the American Heart Association Scientific Sessions 2022
- 07 Nov 2022 Results (n=4420 ) assessing whether benefits of Apixaban Over Warfarin are preserved independent of Warfarin time in therapeutic range, presented at the American Heart Association Scientific Sessions 2022
- 19 Sep 2022 Results of secondary analysis of AUGUSTUS presented at the Transcatheter Cardiovascular Therapeutics 2022